Orentas, Rimas

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,898

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 1,815

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Majzner, R. G., Theruvath, J. L., Nellan, A., Heitzeneder, S., Cui, Y., Mount, C. W., Rietberg, S. P., Linde, M. H., Xu, P., Rota, C., et al. (2019) · Clinical Cancer Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 681

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 468

CD19 CAR T cell product and disease attributes predict leukemia remission durability

Finney, O. C., Brakke, H., Rawlings-Rhea, S., Hicks, R., Doolittle, D., Lopez, M., Futrell, B., Orentas, R. J., Li, D., Gardner, R., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 346

Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas

Long, A. H., Highfill, S. L., Cui, Y., Smith, J. P., Walker, A. J., Ramakrishna, S., El-Etriby, R., Galli, S., Tsokos, M. G., Orentas, R. J., et al. (2016) · Cancer Immunology Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 329

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center

Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 120

Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma

Jackson, Z., Roe, A., Sharma, A. A., Lopes, F. B. T. P., Talla, A., Kleinsorge-Block, S., Zamborsky, K., Schiavone, J., Manjappa, S., Schauner, R., et al. (2020) · Frontiers in Immunology

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 102

Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: real-world experience and cost analysis in India

Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., Lionel, S. A., Selvarajan, S., Korula, A., Abraham, A., George, B., et al. (2023) · Bone Marrow Transplantation

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 89

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 88